![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 13, 11064-11068, March 29, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, November 26, 2001, and in revised form, January 14, 2002
In creating an allelic variant of mouse
Apoe designed to resemble human apolipoprotein E4 (apoE4),
we generated hypomorphic apoE (hypoE) mice that express only ~5% of
normal apoE mRNA levels in all tissues. Insertion of a
neo cassette flanked by loxP sites in the third
intron of Apoe reduced expression of the Arg-61 allelic variant in hypoE mice and resulted in plasma apoE levels that were
~2-5% of normal. Unlike other mouse models with low levels of
circulating apoE, hypoE mice had a nearly normal lipoprotein cholesterol profile when fed a chow diet. Further reduction of apoE
expression in hypoE/Apoe Apolipoprotein E (apoE)1
is an important structural and functional protein component of
lipoproteins that plays a prominent role in lipid metabolism in plasma
and in the central nervous system (1, 2). As a high affinity ligand for
the low density lipoprotein (LDL) receptor, the LDL receptor-related
protein, and heparan sulfate proteoglycans, apoE mediates the uptake of plasma remnant lipoproteins by the liver (3, 4). In addition, apoE
participates in diverse biological processes, such as intracellular cholesterol utilization (5), cell growth (6), immunoregulation (7-9),
and neuronal growth and repair (2).
Tissue-specific control elements in the Apoe gene restrict
its expression to hepatocytes (10), astrocytes (11), skin fibroblasts (12), adipocytes, and macrophages (13). Hepatocyte-derived apoE, the
major source of plasma apoE (14), is responsible for receptor-mediated
uptake of remnant lipoproteins in the liver by the secretion-capture
pathway (15, 16). ApoE secreted by hepatocytes into the space of Disse
associates with incoming remnant lipoproteins and with heparan sulfate
proteoglycans bound to hepatic sinusoidal surfaces. This local
enrichment in apoE facilitates remnant clearance through
receptor-mediated processes. In the brain, astrocytes are the major
source of apoE, which serves in lipid homeostasis in the central
nervous system (17-19). Macrophage-derived apoE promotes remnant
lipoprotein uptake and retards the development of atherosclerosis in
Apoe The transplantation of wild type (WT) bone marrow into
Apoe Recently, we generated an allelic variant of murine apoE, Arg-61, by
gene targeting (33). The targeting vector included a floxed neomycin
(neo) cassette in the third intron to follow the mutation.
Removal of the neo cassette by Cre-mediated recombination resulted in normal apoE expression levels. However, its retention resulted in hypomorphic apoE (hypoE) mice. HypoE mice express reduced
levels of apoE mRNA (~5% of normal) in all tissues examined, giving rise to ~2-5% of normal apoE levels in plasma. Other
examples of hypomorphic genes created in mice by inserting a
neo cassette into an intron have been described
(34-38).
Here we report that the hypoE mice have a nearly normal lipoprotein
profile when fed a chow diet, but they are very susceptible to
diet-induced hypercholesterolemia. The hypercholesterolemia can be
reversed in Mx1-Cre transgenic hypoE mice by removing the neo cassette following induction of Cre recombinase with
polyinosinic-polycytidylic ribonucleic acid (pIpC). This induction
results in restoration of normal levels of plasma apoE.
Thus, hypoE mice are a new model of reduced apoE expression that will
provide additional insight into the physiological roles of apoE.
Moreover, hypoE mice represent a unique opportunity to study the role
of tissue-specific expression of apoE by using Cre-loxP technology.
Generation of a Hypomorphic Allele of Apoe--
A sequence
replacement gene-targeting strategy was previously used to substitute
arginine for the mouse equivalent of human Thr-61 as described (Fig.
1A) (33). Chimeric mice harboring a mutant Apoe
allele, Apoeneo+, in which intron 3 contained a
neo cassette flanked by loxP sites, were crossed
with C57BL/6 female mice to generate Apoeneo+/WT
mice. These heterozygous mice were intercrossed to generate
Apoeneo+/neo+ mice. The mice were weaned at 21 days of age and housed in a barrier facility with a 12-h light/12-h
dark cycle. Unless otherwise noted, they were fed a chow diet
containing 4.5% fat (Ralston Purina, St. Louis, MO).
Breeding Apoeneo+/neo+ Mice Expressing a
Cre Transgene--
Apoeneo+/neo+ mice
were crossed with inducible Mx1-Cre transgenic mice (39). Cre
expression was induced in Mx1-Cre transgenic mice with a 250-µg
intraperitoneal injection of pIpC (Sigma) (39, 40).
Northern Blot Analysis of Total RNA--
After extraction from
several tissues and organs with Triazol reagent
(Invitrogen), total RNA (~20 µg) was electrophoresed in a
1% agarose gel containing 20% formaldehyde, transferred to Hybond
membrane (Amersham Biosciences), and hybridized to a mouse apoE
cDNA probe labeled with [32P]dCTP in Quickhyb
solution (Stratagene, La Jolla, CA) at 65 °C overnight. The blot was
washed in 0.3× standard sodium citrate (150 mM NaCl, 15 mM sodium citrate) and 0.1% SDS at 55 °C for 1 h
and exposed to x-ray film overnight. A second blot of identical samples
run on the same gel was hybridized with a mouse Lipid and Lipoprotein Determination--
Lipids and lipoproteins
were measured in 8-15-week-old male mice that had been fasted for
4 h, anesthetized, and bled by retro-orbital puncture.
Lipoproteins were fractionated by fast performance liquid chromatography (FPLC) on a Superose 6 column (Amersham Biosciences), and plasma was examined by agarose gel electrophoresis (Universal Gel/8, Helena Laboratories, Beaumont, TX). Cholesterol and triglyceride levels in plasma and FPLC fractions were determined with colorimetric assays (Spectrum (Abbott) and Triglycerides (Roche Molecular
Biochemicals), respectively). Statistical analysis was performed with
the nonparametric Mann-Whitney test.
ApoE and ApoB Quantitation--
Fasted mouse plasma was
subjected to SDS-PAGE with 10-20% or 4-15% gels and transferred to
nitrocellulose. Western blotting was performed with rabbit antisera
against mouse apoE (33) and apoB. Polyclonal antisera against mouse
apoB100 and apoB48 were raised using mouse LDL (d = 1.006-1.063 g/ml) isolated from Ldlr
Western blots were incubated with primary antibodies at a dilution of
1:5000, and bound primary antibody was detected by a horseradish
peroxidase-conjugated anti-rabbit antibody (Invitrogen). Signals were
generated by incubating membranes with chemiluminescent reagent
(Amersham Biosciences) and exposing them to x-ray film (Eastman Kodak
Co.). Signals were quantified with a phosphor imager and quantification
software (Bio-Rad QUANTITY ONE).
Diet-induced Hypercholesterolemia--
To induce
hypercholesterolemia, mice were fed a high fat Western diet (21% fat,
0.12% cholesterol) (Harlan Teklad, Madison, WI) or the Paigen diet
(16% fat, 1.25% cholesterol, 0.5% cholic acid) (ICN, Costa Mesa, CA)
for 3 weeks.
Generation of a Hypomorphic Apoe Allele--
The hypoE mice
expressing reduced levels of apoE were generated by homologous
recombination in embryonic stem cells. A neo cassette
flanked by loxP sites was inserted into Apoe
intron 3 to help follow the replacement of the human equivalent of
Thr-61 by an arginine (Fig.
1A) (33). Correctly targeted
embryonic stem cell clones were injected into blastocysts, and chimeric mice were crossed with C57BL/6 mice to generate mice that were heterozygous for the neo cassette
(ApoeWT/neo+). Heterozygous mice were
intercrossed to produce homozygous hypoE mice
(Apoeneo+/neo+).
Characterization of HypoE Mice--
The apoE mRNA levels in
the liver, brain, and spleen in hypoE mice were ~5% of those in WT
mice, suggesting a common mechanism for the reduced expression of the
targeted allele (Fig. 1B). Other organs and tissues that
normally express low levels of apoE gave barely detectable signals. The
plasma apoE levels in male hypoE mice were ~2-5% of those in WT
mice (Fig. 1C). Female mice expressed similar levels, and
male hypoE mice were used to characterize the lipoprotein phenotype. In
chow-fed mice, the total plasma cholesterol and triglyceride levels
were slightly higher in hypoE mice than in WT mice (98 ± 14 versus 65 ± 5 mg/dl, n = 7, p = 0.003; 49 ± 14 versus 26 ± 8 mg/dl, n = 7, p = 0.007, respectively). However, the lipoprotein cholesterol profiles were similar in hypoE,
WT, and Arg-61 Cre-deleted mice (Fig. 2).
HypoE mice had slightly more cholesterol in the VLDL, intermediate
density lipoproteins, and LDL lipoprotein fractions than the WT mice.
Most of the plasma cholesterol in the hypoE mice was associated with
HDL, as in WT mice (65-70% versus 75-80% in WT mice)
(Table I). This finding is in contrast to
Apoe
As shown by SDS-PAGE Western blot analysis, hypoE mice had lower levels
of apoB100 and higher levels of apoB48 in plasma than WT mice (Fig.
3). The hypoE mice and
Apoe
The effect of a further reduction in apoE expression on lipoprotein
metabolism was examined by crossing hypoE and
Apoe Diet-induced Hypercholesterolemia in HypoE Mice--
Next, the
susceptibility of hypoE mice to diet-induced hypercholesterolemia was
determined. On a high fat Western diet (21% fat, 0.12% cholesterol),
hypoE mice had higher plasma levels of cholesterol (238 ± 63 versus 133 ± 25 mg/dl, n = 6, p = 0.003) and triglyceride (93 ± 23 versus 22 ± 13 mg/dl, n = 6, p < 0.001) than WT mice. FPLC analysis revealed an
increase of cholesterol, mainly in the HDL and VLDL fractions, in hypoE
mice (Fig. 4). In contrast, the Paigen
diet (16% fat, 1.25% cholesterol, 0.5% cholic acid) markedly
increased the accumulation of all classes of remnant lipoproteins in
hypoE mice, and their plasma cholesterol and triglyceride levels were
much higher than those of WT mice (1146 ± 141 versus
227 ± 31 mg/dl, n = 6, p < 0.001 and 61 ± 33 versus 18 ± 7 mg/dl,
n = 6, p = 0.01, respectively). Similar
responses to these two diets have been observed in other mouse models
of low level apoE expression (20, 21). The hypercholesterolemia in
hypoE mice was fully reversed 3 weeks after resumption of a chow diet
(Fig. 5). These results demonstrate that
hypoE mice are far more susceptible to diet-induced
hypercholesterolemia than WT mice and that very different lipoprotein
profiles and plasma lipid levels can be obtained using different diet
formulations.
The Effects of Gene Repair on Plasma Lipoprotein Metabolism in
HypoE Mice--
We have previously demonstrated that removal of the
neo cassette from the targeted Apoe allele by
crossing hypoE mice with Cre-deleted transgenic mice resulted in
organ-wide reversal of the hypomorphic effect (33). Levels of apoE
mRNA in Cre-deleted mice are identical to WT in the liver, brain,
and spleen, and plasma lipid levels and lipoprotein profiles are
similar (33). To test the effects of conditional gene repair on plasma
lipid metabolism, we crossed hypoE mice with inducible Mx1-Cre
transgenic mice. Induction of these mice has been demonstrated to lead
to Cre-mediated recombination in the liver and bone marrow (39, 40).
Uninduced Mx1-Cre transgenic hypoE mice had plasma apoE levels
identical to those of nontransgenic hypoE mice, and they were equally
susceptible to diet-induced hypercholesterolemia (not shown). A single
intraperitoneal injection of 250 µg of pIpC in Mx1-Cre transgenic
hypoE mice increased plasma apoE levels within 2 days, and normal
plasma apoE levels were restored within 10 days (Fig.
6). Restoration of plasma apoE levels
completely reversed diet-induced hypercholesterolemia, resulting in a
plasma cholesterol level of 65 mg/dl and a WT lipoprotein profile in two separate mice (not shown).
This study shows that introducing a neo cassette
flanked by loxP sites into Apoe intron 3 to
create a human apoE4-like allelic variant (Arg-61 apoE) results in mice
with reduced apoE mRNA expression in all tissues. The generation of
a nonproductive splice variant from a major portion of primary RNA
transcripts has been proposed as an explanation for the hypomorphic
effect in other models (35-37). Despite having plasma apoE levels of
~2-5% of normal, hypoE mice have a lipoprotein cholesterol profile
similar to that of WT mice. Significantly, most of the plasma
cholesterol (65-70%) is associated with HDL, as in WT mice. Unlike WT
mice, however, hypoE mice are highly susceptible to diet-induced
hypercholesterolemia, which is rapidly reversed when the mice are fed a
normal chow diet. The reversal of remnant accumulation is consistent
with our conclusion that 2-5% of normal plasma apoE levels can
support effective remnant clearance.
HypoE mice differ from previous mouse models with reduced plasma apoE
levels. For example, several lines of transgenic
Apoe The susceptibility of hypoE mice to hypercholesterolemia induced by the
two diets used was predictable, given the well-documented accumulation
of plasma cholesterol in Apoe Another interesting feature of hypoE mice was the skewing of plasma
apoB100 and apoB48 levels. HypoE mice had lower levels of apoB100 and
higher levels of apoB48 than WT mice. In hypoE mice, apoB100
lipoproteins are probably cleared more rapidly from the circulation by
the LDL receptor, whereas the clearance of apoB48 lipoproteins, which
depend on apoE, may be delayed (3, 43). The LDL receptor-related
protein also may fail to clear apoB48 remnants effectively due to
limiting amounts of circulating apoE, resulting in increased levels of
apoB48. Alternatively, the reduced levels of apoB100 in hypoE mice may
result from decreased apoB100 secretion by the liver. Indeed, hepatic
apoE expression has been reported to promote apoB secretion (28). To
define better the mechanisms that lead to reduced levels of plasma
apoB100 in hypoE mice, it will be necessary to determine the production rate of apoB in vivo and in primary cultures of hepatocytes
from hypoE mice.
The hypoE mouse model also offers the possibility of taking advantage
of emerging Cre-loxP technology. We demonstrate here that in
Mx1-Cre transgenic hypoE mice, removal of the neo cassette by Cre-mediated recombination restored normal plasma apoE levels following induction of Cre recombinase. By crossing hypoE mice with
tissue-specific Cre transgenic mice, it will be possible to restore
normal levels of apoE expression in selected tissue. For example,
crossing hypoE mice with Mac1-Cre transgenic mice obtained from Dr. G. Kollias (available at www.fleming.gr) will produce mice in which apoE
expression is fully restored only in macrophages. These mice could help
to elucidate the role of macrophage-derived apoE in plasma lipoprotein
metabolism and in the prevention of atherosclerosis. Restoring normal
plasma apoE levels in Mx1-Cre and in tissue- and cell lineage-specific
Cre transgenic hypoE mice, such as astrocyte-, oligodendrocyte-, and
neuron-specific Cre, represents a unique way to study the biological
roles of apoE in the brain. Achieving physiological and permanently
sustained levels of apoE expression after Cre-mediated excision of the
neo cassette represents an approach to study the
contribution of apoE to atherosclerosis regression not available in
current models. Moreover, when WT hypoE mice become available,
isoform-specific differences between Arg-61 apoE and WT apoE will
provide the means to determine the contribution of apoE4 domain
interaction as a distinguishing feature between apoE4 and apoE3 in
atherosclerosis regression.
In summary, we report the development of mice with reduced apoE
expression or hypoE mice. The reversibility of the hypomorphic effect
in hypoE mice provides the opportunity for an expanded study of the
role of tissue-derived apoE in existing tissue-specific and inducible
Cre transgenic mice (44) and in new lines as they become available.
We thank Dr. Kimberly Buhman for help with
the statistical analysis, Dr. Joachim Herz (University of Texas
Southwestern Medical Center) for providing Mx1-Cre transgenic mice,
Brian Auerbach for manuscript preparation, Gary Howard and Stephen
Ordway for editorial assistance, and Jack Hull and John Carroll for graphics.
*
This work was supported in part by National Institutes of
Health Grant HL47660 (to K. H. W.), University of California
Tobacco-Related Disease Research Program Grant 10KT-0318 (to
R. L. R), and a fellowship from the Heart and Stroke Foundation of
Canada (to R. L. R).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, January 15, 2002, DOI 10.1074/jbc.M111222200
The abbreviations used are:
apo, apolipoprotein;
LDL, low density lipoprotein(s);
VLDL, very low density lipoprotein(s);
HDL, high density lipoprotein(s);
WT, wild type;
neo, neomycin;
FPLC, fast performance liquid chromatography;
hypoE, hypomorphic apoE;
pIpC, polyinosinic-polycytidylic ribonucleic
acid.
Hypomorphic Apolipoprotein E Mice
A NEW MODEL OF CONDITIONAL GENE REPAIR TO EXAMINE APOLIPOPROTEIN
E-MEDIATED METABOLISM*
§ and
§¶
Gladstone Institutes of Cardiovascular
Disease and Neurological Disease, San Francisco, California
94141-9100, § Cardiovascular Research Institute, and
¶ Department of Pathology, University of California,
San Francisco, California 94143
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
heterozygous mice
led to an increase in remnant lipoprotein-associated cholesterol
levels, demonstrating that hypoE mice express close to the threshold
level of Arg-61 apoE required for a normal lipoprotein profile. Unlike
wild type mice, hypoE mice were susceptible to diet-induced
hypercholesterolemia, which was fully reversed within 3 weeks after
resumption of a chow diet. In Mx1-Cre transgenic hypoE mice, plasma
apoE levels returned to normal within 10 days after gene repair and
removal of the neo cassette following induction of Cre
recombinase. HypoE mice provide the opportunity for conditional gene
repair by crossing with inducible or lineage/cell type-specific Cre
transgenic mice, generating new models to dissect the roles of apoE in
atherosclerosis regression, immunoregulation, and neurodegeneration.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice (20-22). ApoE also participates
in the regression of atherosclerosis (23, 24), contributes to the
production of very low density lipoprotein (VLDL) triglycerides (25,
26), impairs VLDL-triglyceride lipolysis (27), and enhances the
production of VLDL-apoB (28). In addition, apoE has been suggested to
participate in the regulation of inflammatory immune responses that
protect against bacterial infection (29) and to act as an antioxidant
to protect against atherosclerosis (30).
/
mice as a source of non-liver-derived
apoE demonstrated that levels of plasma apoE equivalent to 10% of
normal are sufficient to reduce plasma cholesterol levels to a normal
range (20, 21, 31). In transgenic Apoe
/
mice
expressing WT apoE in the adrenal gland, 3% but not 1% of normal
plasma apoE levels substantially reduced plasma cholesterol levels
(32). However, in the bone marrow transplantation model, low levels of
apoE failed to restore a normal plasma lipoprotein profile. Unlike WT
mice, which transport ~75-80% of their plasma cholesterol in high
density lipoproteins (HDL), Apoe
/
mice
transplanted with WT bone marrow and expressing 2-5% of plasma apoE
transport ~30%-40% of their plasma cholesterol in HDL (31).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-actin probe.
Signals were quantified with a phosphor imager and
quantification software (Bio-Rad QUANTITY ONE).
/
mouse
plasma by sequential density ultracentrifugation. New Zealand White
rabbits were immunized with 100 µg of purified mouse LDL emulsified
in complete Freund's adjuvant. Rabbits were boosted twice with antigen
emulsified in incomplete Freund's adjuvant.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (29K):
[in a new window]
Fig. 1.
Generation of hypoE mice.
A, targeting strategy. Homologous recombination of the
targeting vector with the Apoe locus results in inserting a
neo cassette into intron 3 and converts the equivalent of
human Thr-61 to an arginine as previously described (33). B,
Northern blot demonstration of reduced expression of the
Apoe hypomorphic allele. Total RNA from the liver, brain,
and spleen was isolated from WT mice and hypoE mice and subjected to
Northern blot analysis with apoE cDNA probe or a control mouse
-actin probe. C, Western blot of mouse plasma; comparison
of hypoE mouse plasma (1 µl) with serially diluted WT mouse
plasma.
/
mice engineered to express levels of
apoE ~2-5% of WT (31). In these mice, a significant portion of
plasma cholesterol is associated with VLDL and LDL lipoproteins, and
only ~30-40% of plasma cholesterol is associated with HDL (31).
Agarose gel electrophoresis confirmed the nearly normal lipoprotein
profile in hypoE mice indicated by FPLC (Fig. 2, inset).

View larger version (28K):
[in a new window]
Fig. 2.
Plasma lipoprotein profiles of WT, hypoE, and
Arg-61 Cre-deleted mice. Plasma from five fasted mice was pooled
and fractionated by FPLC. Fractions corresponding to the various
lipoprotein classes are indicated. Inset, mouse plasma
separated by agarose gel electrophoresis. Lane 1,
WT mouse plasma; lane 2,
Apoe
/
plasma; lane 3,
hypoE mouse plasma.
Cholesterol distribution among plasma lipoprotein fractions from
wild type and hypoE mice fed a chow diet
/
mice had very similar levels of
apoB100, approximately 75% lower than in WT mice as judged by
densitometry. In contrast, hypoE mice had 8-fold more apoB48 than WT
mice.

View larger version (42K):
[in a new window]
Fig. 3.
Relative levels of apoB100 and apoB48 in
mouse plasma. Plasma from fasted mice was resolved by SDS-PAGE,
and apoB was detected by Western blotting. Lane
1, WT mouse plasma; lane 2,
Apoe
/
plasma; lanes 3 and 4, plasma from two hypoE mice.
/
mice. Heterozygous
Apoeneo+/
mice did not have significantly
higher plasma cholesterol and triglyceride levels than hypoE mice
(114 ± 32 versus 98 ± 14 mg/dl, n = 7, p = 0.164, and 58 ± 16 versus 49 ± 14 mg/dl, n = 7, p = 0.47). However, Apoeneo+/
mice carried more plasma cholesterol as remnant lipoproteins than hypoE
mice (Table I). Taken together, these results suggest that hypoE mice
express close to the lower limit of apoE required to maintain a nearly
normal lipoprotein profile.

View larger version (17K):
[in a new window]
Fig. 4.
Plasma lipoprotein profiles of mice fed the
high fat Western diet. Mice were maintained on the diet for 3 weeks. Plasma from five fasted mice was pooled and resolved by FPLC.
Fractions corresponding to the different lipoprotein classes are
indicated.

View larger version (24K):
[in a new window]
Fig. 5.
Reversal of diet-induced hypercholesterolemia
in mice. Mice were maintained on the Paigen diet for 3 weeks.
Plasma from five fasted mice was pooled and resolved by FPLC. Diet-fed
mice were returned to a chow diet for 3 weeks, and plasma from fasted
mice was resolved by FPLC. Fractions corresponding to the different
lipoprotein classes are indicated.

View larger version (40K):
[in a new window]
Fig. 6.
Induction of apoE expression in Mx1-Cre
transgenic hypoE mice. Mice were bled before and 2 and 10 days
after induction with pIpC. Plasma was resolved by SDS-PAGE, and apoE
was detected by Western blotting. Lanes A and
B represent plasma from two separate hypoE mice.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice expressing WT mouse apoE in the
adrenal gland have reduced plasma cholesterol levels with 3% but not
with 1% of WT plasma apoE levels (32). The lipoprotein profile of the
transgenic Apoe
/
mice expressing 3% of WT
apoE was not reported in the study and therefore cannot be compared
with hypoE mice. Apoe
/
mice engineered to
express apoE from nonhepatic sources at ~2-5% of normal levels by
bone marrow transplantation have reduced plasma cholesterol levels;
however, only ~30-40% of their plasma cholesterol is associated
with HDL (31) versus 65-70% in hypoE mice and 75-80% in
WT mice. We speculate that the presence of hepatocyte-derived apoE in
the hypoE mice may explain the difference in remnant lipoprotein metabolism between hypoE mice and mice expressing low levels of plasma
apoE from nonhepatic sources. The hypoE mouse model demonstrates that
~2-5% of normal plasma apoE is close to the threshold level of apoE
required for normal lipoprotein metabolism in mice fed a chow diet. A
potential contributing factor to this observation may be that the
Arg-61 apoE is more effective in remnant clearance than WT apoE.
However, we have demonstrated that plasma lipid levels and lipoprotein
profiles are similar in WT and gene-targeted mice expressing normal
levels of Arg-61 apoE, suggesting that, if there are differences, they
may be small (33). To evaluate the potential differences between the
Arg-61 and WT apoE isoforms, we are currently generating WT hypoE mice
by inserting a neo cassette flanked by loxP sites
into intron 3 of the WT Apoe gene.
/
mice and in
Apoe
/
mice expressing low levels of mouse or
human apoE (20-22, 31, 32, 41, 42). However, the hypoE mouse model
provides the opportunity to produce a spectrum of lipoprotein and
plasma cholesterol levels by dietary manipulation. Plasma cholesterol
levels in hypoE mice increased by 2.5-fold on the high fat Western diet
and by 8-12-fold on the Paigen diet. As a result, plasma lipid and
lipoprotein levels can be more tightly modulated by diet composition in
hypoE mice than in WT mice.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Gladstone
Institute of Cardiovascular Disease, P.O. Box 419100, San Francisco, CA
94141-9100. Tel.: 415-826-7500; Fax: 415-285-5632; E-mail: kweisgraber@gladstone.ucsf.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Mahley, R. W.
(1988)
Science
240,
622-630 2.
Weisgraber, K. H.,
and Mahley, R. W.
(1996)
FASEB J.
10,
1485-1494[Abstract] 3.
Mahley, R. W.,
and Ji, Z.-S.
(1999)
J. Lipid Res.
40,
1-16 4.
Cooper, A. D.
(1997)
J. Lipid Res.
38,
2173-2192[Abstract] 5.
Reyland, M. E.,
and Williams, D. L.
(1991)
J. Biol. Chem.
266,
21099-21104 6.
Ishigami, M.,
Swertfeger, D. K.,
Granholm, N. A.,
and Hui, D. Y.
(1998)
J. Biol. Chem.
273,
20156-20161 7.
Avila, E. M.,
Holdsworth, G.,
Sasaki, N.,
Jackson, R. L.,
and Harmony, J. A. K.
(1982)
J. Biol. Chem.
257,
5900-5909 8.
Hui, D. Y.,
Harmony, J. A. K.,
Innerarity, T. L.,
and Mahley, R. W.
(1980)
J. Biol. Chem.
255,
11775-11781 9.
Pepe, M. G.,
and Curtiss, L. K.
(1986)
J. Immunol.
136,
3716-3723[Abstract] 10.
Allan, C. M.,
Taylor, S.,
and Taylor, J. M.
(1997)
J. Biol. Chem.
272,
29113-29119 11.
Grehan, S.,
Tse, E.,
and Taylor, J. M.
(2001)
J. Neurosci.
21,
812-822 12.
Grehan, S.,
Allan, C.,
Tse, E.,
Walker, D.,
and Taylor, J. M.
(2001)
J. Invest. Dermatol.
116,
77-84[CrossRef][Medline]
[Order article via Infotrieve] 13.
Shih, S.-J.,
Allan, C.,
Grehan, S.,
Tse, E.,
Moran, C.,
and Taylor, J. M.
(2000)
J. Biol. Chem.
275,
31567-31572 14.
Linton, M. F.,
Gish, R.,
Hubl, S. T.,
Bütler, E.,
Esquivel, C.,
Bry, W. I.,
Boyles, J. K.,
Wardell, M. R.,
and Young, S. G.
(1991)
J. Clin. Invest.
88,
270-281[Medline]
[Order article via Infotrieve] 15.
Ji, Z.-S.,
Fazio, S.,
Lee, Y.-L.,
and Mahley, R. W.
(1994)
J. Biol. Chem.
269,
2764-2772 16.
Shimano, H.,
Namba, Y.,
Ohsuga, J.,
Kawamura, M.,
Yamamoto, K.,
Shimada, M.,
Gotoda, T.,
Harada, K.,
Yazaki, Y.,
and Yamada, N.
(1994)
J. Clin. Invest.
93,
2215-2223[Medline]
[Order article via Infotrieve] 17.
Boyles, J. K.,
Zoellner, C. D.,
Anderson, L. J.,
Kosik, L. M.,
Pitas, R. E.,
Weisgraber, K. H.,
Hui, D. Y.,
Mahley, R. W.,
Gebicke-Haerter, P. J.,
Ignatius, M. J.,
and Shooter, E. M.
(1989)
J. Clin. Invest.
83,
1015-1031[Medline]
[Order article via Infotrieve] 18.
Pitas, R. E.,
Boyles, J. K.,
Lee, S. H.,
Hui, D.,
and Weisgraber, K. H.
(1987)
J. Biol. Chem.
262,
14352-14360 19.
Pitas, R. E.,
Boyles, J. K.,
Lee, S. H.,
Foss, D.,
and Mahley, R. W.
(1987)
Biochim. Biophys. Acta
917,
148-161[Medline]
[Order article via Infotrieve] 20.
Linton, M. F.,
Atkinson, J. B.,
and Fazio, S.
(1995)
Science
267,
1034-1037 21.
Boisvert, W. A.,
Spangenberg, J.,
and Curtiss, L. K.
(1995)
J. Clin. Invest.
96,
1118-1124[Medline]
[Order article via Infotrieve] 22.
Bellosta, S.,
Mahley, R. W.,
Sanan, D. A.,
Murata, J.,
Newland, D. L.,
Taylor, J. M.,
and Pitas, R. E.
(1995)
J. Clin. Invest.
96,
2170-2179[Medline]
[Order article via Infotrieve] 23.
Tsukamoto, K.,
Tangirala, R.,
Chun, S. H.,
Puré, E.,
and Rader, D. J.
(1999)
Arterioscler. Thromb. Vasc. Biol.
19,
2162-2170 24.
Desurmont, C.,
Caillaud, J.-M.,
Emmanuel, F.,
Benoit, P.,
Fruchart, J. C.,
Castro, G.,
Branellec, D.,
Heard, J.-M.,
and Duverger, N.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
435-442 25.
Kuipers, F.,
Jong, M. C.,
Lin, Y.,
van Eck, M.,
Havinga, R.,
Bloks, V.,
Verkade, H. J.,
Hofker, M. H.,
Moshage, H.,
van Berkel, T. J. C.,
Vonk, R. J.,
and Havekes, L. M.
(1997)
J. Clin. Invest.
100,
2915-2922[Medline]
[Order article via Infotrieve] 26.
Huang, Y.,
Liu, X. Q.,
Rall, S. C., Jr.,
Taylor, J. M.,
von Eckardstein, A.,
Assmann, G.,
and Mahley, R. W.
(1998)
J. Biol. Chem.
273,
26388-26393 27.
Huang, Y., Ji, Z.-S.,
Brecht, W. J.,
Rall, S. C., Jr.,
Taylor, J. M.,
and Mahley, R. W.
(1999)
Arterioscler. Thromb. Vasc. Biol.
19,
2952-2959 28.
Maugeais, C.,
Tietge, U. J. F.,
Tsukamoto, K.,
Glick, J. M.,
and Rader, D. J.
(2000)
J. Lipid Res.
41,
1673-1679 29.
Mahley, R. W.,
and Rall, S. C., Jr.
(2000)
Annu. Rev. Genomics Hum. Genet.
1,
507-537[CrossRef][Medline]
[Order article via Infotrieve]
30.
Tangirala, R. K.,
Praticó, D.,
FitzGerald, G. A.,
Chun, S.,
Tsukamoto, K.,
Maugeais, C.,
Usher, D. C.,
Puré, E.,
and Rader, D. J.
(2001)
J. Biol. Chem.
276,
261-266 31.
Hasty, A. H.,
Linton, M. F.,
Swift, L. L.,
and Fazio, S.
(1999)
J. Lipid Res.
40,
1529-1538 32.
Thorngate, F. E.,
Rudel, L. L.,
Walzem, R. L.,
and Williams, D. L.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
1939-1945 33.
Raffaï, R. L.,
Dong, L.-M.,
Farese, R. V., Jr.,
and Weisgraber, K. H.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
11587-11591 34.
Carmeliet, P.,
Ferreira, V.,
Breier, G.,
Pollefeyt, S.,
Kieckens, L.,
Gertsenstein, M.,
Fahrig, M.,
Vandenhoeck, A.,
Harpal, K.,
Eberhardt, C.,
Declercq, C.,
Pawling, J.,
Moons, L.,
Collen, D.,
Risau, W.,
and Nagy, A.
(1996)
Nature
380,
435-439[CrossRef][Medline]
[Order article via Infotrieve] 35.
Jacks, T.,
Shih, T. S.,
Schmitt, E. M.,
Bronson, R. T.,
Bernards, A.,
and Weinberg, R. A.
(1994)
Nat. Genet.
7,
353-361[CrossRef][Medline]
[Order article via Infotrieve] 36.
Meyers, E. N.,
Lewandoski, M.,
and Martin, G. R.
(1998)
Nat. Genet.
18,
136-141[CrossRef][Medline]
[Order article via Infotrieve] 37.
Nagy, A.,
Moens, C.,
Ivanyi, E.,
Pawling, J.,
Gertsenstein, M.,
Hadjantonakis, A.-K.,
Pirity, M.,
and Rossant, J.
(1998)
Curr. Biol.
8,
661-664[CrossRef][Medline]
[Order article via Infotrieve] 38.
Mohn, A. R.,
Gainetdinov, R. R.,
Caron, M. G.,
and Koller, B. H.
(1999)
Cell
98,
427-436[CrossRef][Medline]
[Order article via Infotrieve] 39.
Rohlmann, A.,
Gotthardt, M.,
Hammer, R. E.,
and Herz, J.
(1998)
J. Clin. Invest.
101,
689-695[Medline]
[Order article via Infotrieve] 40.
Kühn, R.,
Schwenk, F.,
Aguet, M.,
and Rajewsky, K.
(1995)
Science
269,
1427-1429 41.
Piedrahita, J. A.,
Zhang, S. H.,
Hagaman, J. R.,
Oliver, P. M.,
and Maeda, N.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
4471-4475 42.
Plump, A. S.,
Smith, J. D.,
Hayek, T.,
Aalto-Setälä, K.,
Walsh, A.,
Verstuyft, J. G.,
Rubin, E. M.,
and Breslow, J. L.
(1992)
Cell
71,
343-353[CrossRef][Medline]
[Order article via Infotrieve] 43.
Véniant, M. M.,
Zlot, C. H.,
Walzem, R. L.,
Pierotti, V.,
Driscoll, R.,
Dichek, D.,
Herz, J.,
and Young, S. G.
(1998)
J. Clin. Invest.
102,
1559-1568[Medline]
[Order article via Infotrieve] 44.
Nagy, A.
(2000)
Genesis
26,
99-109[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. E. MacLean, W. S. M. Chiu, C. Ma, J. F. McManus, R. A. Davey, R. Cameron, A. J. Notini, and J. D. Zajac A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice Physiol Genomics, March 10, 2008; 33(1): 133 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hsueh, E. D. Abel, J. L. Breslow, N. Maeda, R. C. Davis, E. A. Fisher, H. Dansky, D. A. McClain, R. McIndoe, M. K. Wassef, et al. Recipes for Creating Animal Models of Diabetic Cardiovascular Disease Circ. Res., May 25, 2007; 100(10): 1415 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xu, A. Bernardo, D. Walker, T. Kanegawa, R. W. Mahley, and Y. Huang Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus. J. Neurosci., May 10, 2006; 26(19): 4985 - 4994. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Karackattu, B. Trigatti, and M. Krieger Hepatic Lipase Deficiency Delays Atherosclerosis, Myocardial Infarction, and Cardiac Dysfunction and Extends Lifespan in SR-BI/Apolipoprotein E Double Knockout Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 548 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Carpenter, Y. Lin, S. Stoll, R. L. Raffai, R. McCuskey, and R. Wang VEGF is crucial for the hepatic vascular development required for lipoprotein uptake Development, July 15, 2005; 132(14): 3293 - 3303. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhang, M. H. Picard, E. Vasile, Y. Zhu, R. L. Raffai, K. H. Weisgraber, and M. Krieger Diet-Induced Occlusive Coronary Atherosclerosis, Myocardial Infarction, Cardiac Dysfunction, and Premature Death in Scavenger Receptor Class B Type I-Deficient, Hypomorphic Apolipoprotein ER61 Mice Circulation, June 28, 2005; 111(25): 3457 - 3464. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Davignon Apolipoprotein E and Atherosclerosis: Beyond Lipid Effect Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 267 - 269. [Full Text] [PDF] |
||||
![]() |
R. L. Raffai, S. M. Loeb, and K. H. Weisgraber Apolipoprotein E Promotes the Regression of Atherosclerosis Independently of Lowering Plasma Cholesterol Levels Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 436 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Raffai, A. H. Hasty, Y. Wang, S. E. Mettler, D. A. Sanan, M. F. Linton, S. Fazio, and K. H. Weisgraber Hepatocyte-derived ApoE Is More Effective than Non-hepatocyte-derived ApoE in Remnant Lipoprotein Clearance J. Biol. Chem., March 21, 2003; 278(13): 11670 - 11675. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||